News
People with the rare growth hormone disorder acromegaly have a significantly higher risk of developing various types of ...
People with the rare growth hormone disorder acromegaly have a significantly higher risk of developing various types of ...
GlobalData on MSN1d
Crinetics reveals new data from acromegaly therapy programmeThe Palsonify-treated subjects maintained control, with stable growth hormone levels, symptom scores, and pituitary tumour ...
News-Medical.Net on MSN22h
Acromegaly linked to higher cancer riskPeople with the rare growth hormone disorder acromegaly have a significantly higher risk of developing various types of cancer, often at ages younger than typically seen in the general population, ...
Data show that PALSONIFY was well tolerated and IGF-1 levels remained stably controlled during long-term open label ...
Crinetics shares PATHFNDR trial data showing oral Palsonify maintained hormone and symptom control in acromegaly patients ...
Most adults with acromegaly reduced IGF-1 levels and improved acromegaly symptoms with once-monthly subcutaneous octreotide ...
Stocktwits on MSN1d
Crinetics Pharma’s Oral Drug Shows Lasting Relief For Acromegaly Patients In Latest Study; Retail Buzz BuildsRetail chatter around Crinetics Pharmaceuticals picked up late Sunday after the company released long-term data for its oral ...
SOUTH SAN FRANCISCO, CA, USA I July 14, 2025 I Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback